Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Dispatch

Fatal Case of Chronic Jamestown Canyon Virus Encephalitis Diagnosed by Metagenomic Sequencing in Patient Receiving Rituximab

Figures
Tables
Article Metrics
2
citations of this article
EID Journal Metrics on Scopus
Isaac H. Solomon1Comments to Author , Vijay S. Ganesh1, Guixia Yu, Xian Ding Deng, Michael R. Wilson, Steve Miller, Tracey A. Milligan, Shibani S. Mukerji, Abigail Mathewson, Justin Linxweiler, Darlene Morse, Jana M. Ritter, J. Erin Staples, Holly Hughes, Carolyn V. Gould, Pardis C. Sabeti2, Charles Y. Chiu2, and Anne Piantadosi23
Author affiliations: Brigham and Women’s Hospital, Boston, Massachusetts, USA (I.H. Solomon, V.S. Ganesh, T.A. Milligan); Harvard Medical School, Boston (I.H. Solomon, V.S. Ganesh, T.A. Milligan, S.S. Mukerji, A. Piantadosi); Broad Institute, Cambridge, Massachusetts, USA (V.S. Ganesh, P.C. Sabeti, A. Piantadosi); University of California–San Francisco, San Francisco, California, USA (G. Yu, X.D. Deng, M.R. Wilson, S. Miller, C.Y. Chiu); Massachusetts General Hospital, Boston (S.S. Mukerji, A. Piantadosi); New Hampshire Division of Public Health Services, Concord, New Hampshire, USA (A. Mathewson, J. Linxweiler, D. Morse); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.M. Ritter); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (J.E. Staples, H. Hughes, C.V. Gould); Harvard University, Cambridge (P.C. Sabeti); Harvard T.H. Chan School of Public Health, Boston (P.C. Sabeti); Howard Hughes Medical Institute, Chevy Chase, Maryland, USA (P.C. Sabeti)

Cite This Article

Abstract

A 56-year-old man receiving rituximab who had months of neurologic symptoms was found to have Jamestown Canyon virus in cerebrospinal fluid by clinical metagenomic sequencing. The patient died, and postmortem examination revealed extensive neuropathologic abnormalities. Deep sequencing enabled detailed characterization of viral genomes from the cerebrospinal fluid, cerebellum, and cerebral cortex.

Jamestown Canyon orthobunyavirus (JCV) is a negative-sense RNA virus in the California serogroup. Its tripartite genome comprises small (nucleocapsid), medium (glycoprotein), and large (polymerase) segments. JCV is distributed throughout the United States and Canada and has been isolated from multiple mammals and mosquitoes (1,2). Most infections occur in adults, during the summer, and are asymptomatic, but manifestations can include fever and acute meningoencephalitis (2). Cerebrospinal fluid (CSF) typically shows a lymphocytic pleocytosis with elevated protein and normal glucose. Diagnosis is made by detection of JCV IgM in serum or CSF and confirmed by plaque-reduction neutralization testing to rule out cross-reactivity with other California serogroup viruses (3). Detection of viral RNA in human CSF has rarely been described, with viremia presumed to be of short duration, so reverse transcription PCR (RT-PCR) is not routinely used for diagnosis (35). No specific treatments are available, although intravenous ribavirin has been reported to improve seizures (6). Because of the limited number of cases described, the full range of findings associated with JCV infection is unknown. No fatal cases were reported to the Centers for Disease Control and Prevention (CDC) before 2017, and no autopsy reports have been published (7).

The Case-Patient

Figure 1

Brain imaging and autopsy findings in a case of chronic Jamestown Canyon virus (JCV) meningoencephalitis in a patient receiving rituximab, Boston, Massachusetts, USA. A) Brain magnetic resonance imaging T2-weighted fluid-attenuated inversion recovery showed mild atrophy with secondary ventriculomegaly but was otherwise unremarkable. B) Brain positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose integrated with computed tomography showed global hypometabolism. Color scale ranges from blue-green (hypometabolic) to orange-white (hypermetabolic). C, D) Hematoxylin and eosin stained section of cerebral cortex at low magnification shows loss of neurons and perivascular chronic inflammation (C), compared with a JCV-negative control with a normal complement of cortical neurons (D). E, F) Higher-power magnification of cerebral cortex (E) and hippocampus (F) show microgliosis, microglial nodules, and neuronophagia (arrow). G, H) Severe Purkinje cell loss, Bergmann gliois (arrows), and microgliosis (arrowheads) of the molecular layer are present in the cerebellum (G), compared with a JCV-negative control with normal complement of Purkinje cells (H). I, J) Immunohistochemistry shows abundant perivascular, parenchymal, and leptomeningeal CD3+ T cells (I) and is negative for B-cell lineage–specific activator protein positive B cells (J). Panels C, D, I, and J, original magnification ×100; panels E, F, G, and H, original magnification ×200.

Figure 1. Brain imaging and autopsy findings in a case of chronic Jamestown Canyon virus (JCV) meningoencephalitis in a patient receiving rituximab, Boston, Massachusetts, USA. A) Brain magnetic resonance imaging T2-weighted fluid-attenuated...

A 56-year-old man from New England with a history of mantle cell lymphoma in remission, receiving maintenance rituximab since 2014, had fatigue, arthralgias, and weight loss in summer 2017. He was empirically treated for Lyme disease without improvement, had progressive insomnia and inattention, and was eventually admitted for workup of rapidly progressive dementia in April 2018. On examination, he had impaired arousal and attention (Montreal Cognitive Assessment score 6 of 30). Cranial nerve, tone, strength, sensory, and reflex examinations were normal. Gait was wide-based and slow without ataxia or parkinsonism. Magnetic resonance imaging of the brain showed mild ventriculomegaly attributed to atrophy but was otherwise unremarkable, without contrast enhancement, cortical diffusion restriction, mass lesions, hemorrhage, or infarction (Figure 1). Electroencephalography showed moderate bihemispheric slowing without epileptiform features. CSF from multiple lumbar punctures showed mild lymphocytic pleocytosis (0–22 leukocytes/μL, 83%–98% lymphocytes), elevated total protein (40–116 mg/dL; reference 10–44 mg/dL), and unremarkable glucose (65–78 mg/dL; reference 40–80 mg/dL) (Appendix Table 1). An extensive infectious, autoimmune, and neurodegenerative disease workup was normal (Appendix Table 2).

A CSF sample collected in April 2018 underwent clinical metagenomic next-generation sequencing (mNGS) testing at the University of California–San Francisco (8) and was positive for California encephalitis virus most closely matching JCV, with reads mapping to 2 of the 3 viral genome segments (Appendix Figure 1). Another CSF sample, obtained approximately 3 weeks later in May, was negative for JCV by RT-PCR performed by CDC’s Arboviral Diseases Branch (Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases; Fort Collins, CO, USA); however, concurrent serum JCV RT-PCR was positive. Results of JCV IgM and neutralizing antibody testing were negative for CSF and blood from the samples obtained in May. Concurrent samples had 0% CD20+ circulating lymphocytes (reference 3%–20% lymphocytes), attributed to rituximab treatment, last administered in December 2017.

The patient was treated with intravenous immunoglobulin (total 2 g/kg), followed by a 2-week course of favipiravir, an experimental inhibitor of viral RNA polymerase, without improvement. His mental status deteriorated to a comatose state. He was transitioned to comfort care and died in June 2018, ≈1 year after suspected symptom onset.

At autopsy, the unfixed brain weighed 1,240 g and appeared grossly normal, with no masses, hemorrhage, infarctions, or herniation. Histologic abnormalities were most prominent in the cerebral cortex (particularly frontal and temporal lobes), cerebellum, and hippocampus; milder changes in basal ganglia, thalamus, and brainstem were observed, including severe loss of neurons, diffuse microgliosis with microglial nodules and neuronophagia, and perivascular and parenchymal chronic inflammation (Figure 1). Leptomeninges showed numerous chronic inflammatory cells. No viral inclusions were identified. There was no evidence of lymphoma. Immunohistochemical staining highlighted abundant perivascular, parenchymal, and leptomeningeal T cells with a complete lack of B cells. Formalin-fixed paraffin-embedded brain tissue was positive for JCV by RT-PCR (performed by CDC’s Arboviral Diagnostic and Reference Laboratory); results were negative for immunohistochemistry for flaviviruses and enteroviruses (performed by CDC’s Infectious Diseases Pathology Branch [Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases; Atlanta, GA, USA]).

Figure 2

JCV genome analyses in a case of chronic JCV meningoencephalitis in a patient on rituximab, Boston, Massachusetts, USA. A) Maximum-likelihood phylogenetic tree of the coding region of the JCV small segment (nucleocapsid). Sequences from the patient (bold) were most closely related to a JCV strain isolated from Simsbury, Connecticut, USA (GenBank accession no. EF681842), with ≈70% bootstrap support. Clades A, B1, and B2 are as previously reported (9). B) Single-nucleotide polymorphisms (SNPs) observed between samples from patient in this study. The consensus genome derived from each sample was aligned to a mosquito-derived JCV sequence (GenBank accession nos. HM007356 [S segment], HM007357 [M segment], and HM007358 [L segment], all represented in the figure as HM00735X). For each sample in this study, the light gray bar indicates positions for which there was coverage of >3 reads. Using the sequence derived from CSF as the reference, positions with a SNP are marked with a star; black indicates a synonymous change, and red indicates a nonsynonymous change. Only high-confidence (confirmed) SNPs are shown in this figure; all SNPs observed are shown in Appendix Tables 3, 4. Sequence data is available under National Center for Biotechnology Information BioProject no. PRJNA662969 (GenBank accession nos. MW072986–MW073000). CSF, cerebrospinal fluid; FFPE, formalin-fixed, paraffin-embedded; JCV, Jamestown Canyon virus; L, large; M, medium; S, small.

Figure 2. JCV genome analyses in a case of chronic JCV meningoencephalitis in a patient on rituximab, Boston, Massachusetts, USA. A) Maximum-likelihood phylogenetic tree of the coding region of the JCV small...

Complete or near-complete JCV genomes were recovered from premortem CSF and postmortem cerebellum and cortex tissue (both frozen and formalin-fixed paraffin-embedded) (Table; Appendix Supplementary Methods, Figure 2). Phylogenetic analysis of the small (nucleocapsid) segment showed that sequences from this patient were most closely related to JCV from mosquitoes in Connecticut (Figure 2, panel A) (9). Comparison of JCV genomes between this patient’s CSF, cerebellum, and cortex revealed 27 high-confidence within-patient single-nucleotide polymorphisms (SNPs) (Figure 2, panel B; Appendix Tables 3, 4). For 13 SNPs, the variant present in CSF was different from that in cerebellum and cortex, suggesting evolution over time. For another 4 SNPs, the variant present in cerebellum was different from that in cortex, suggesting compartmentalization. The remaining 10 SNPs could represent either compartmentalization or evolution over time, because only 1 brain tissue (cerebellum or cortex) was sequenced to sufficient depth. Variability was greater in the small segment (nucleocapsid) and medium segment (glycoprotein) than the large segment (polymerase).

Conclusions

We describe an unusual fatal case of chronic JCV encephalitis in a patient who was being treated with rituximab. In contrast to this case, previously described patients with JCV have had acute illness, and JCV infection is rarely fatal (7,10). The neuropathologic findings in this patient, although nonspecific, are similar to those of a cerebellar biopsy from a patient with JCV encephalitis that showed severe loss of Purkinje and granule cells, diffuse microgliosis of the molecular layer, and leptomeningeal inflammation (5).

The lack of distinguishing clinical, radiographic, and pathologic features of JCV underscores the diagnostic utility of clinical mNGS (8). Attributable in part to low incidence and lack of commercially available targeted testing, JCV is often not considered a priori, especially in the setting of chronic progressive neurologic illness. As a further complication, standard clinical testing by serology can be negative in the setting of B-cell–depleting therapy; our patient had negative JCV serologic tests and lack of B lymphocytes by immunohistochemical staining. Similar phenomena have been reported in rituximab-treated patients with other arboviral infections (e.g., Cache Valley orthobunyavirus, Powassan virus, and West Nile virus) who lack detectable antibodies but remain viremic longer than immunocompetent patients, highlighting the importance of nucleic acid–based testing methods (1113).

In addition to diagnosis, mNGS also provides valuable information about pathogen genomics. We report the unique assembly of a JCV genome from human clinical samples, an important advance in the study of JVC pathogenesis, virus evolution, and differences between the enzootic transmission cycle and human infection (14). The functional importance of the identified SNPs could not be evaluated from the genomic data alone; however, none were associated with alterations of potential N-linked glycosylation sites, cysteine bonds, or the conserved fusion domain (15). One SNP that arose between CSF and brain (small segment gA397G; aT109A) also varied between JCV strains with different neurovirulence in mice, although the functional importance is unknown (4).

Although treatment options for JCV infection are largely unexplored, response to antiviral drugs probably depends on initiating treatment early in the disease course and reaching therapeutic levels in the CSF before extensive neuronal loss. Thus, broad-spectrum molecular assays such as mNGS could potentially lead to earlier treatment with improved outcomes (8).

Dr. Solomon is a neuropathologist at Brigham and Women’s Hospital and Harvard Medical School, in Boston, Massachusetts. His primary research interests include viral infections of the central nervous system.

Top

Acknowledgments

We thank the patient’s family for granting permission to publish this information. We also wish to acknowledge contributions by Asmeeta Achari, Sarah Reagan-Steiner, and the molecular pathology and immunohistochemistry teams at CDC’s Infectious Disease Pathology Branch.

This study was supported by the National Institutes of Health (grant no. U19AI110818 awarded to P.C.S, grant no. KL2 TR001100 awarded to A.P., and grant no. R33AI129455 awarded to C.Y.C.), the Charles and Helen Schwab Foundation (grant awarded to C.Y.C.), and a Broadnext10 gift from the Broad Institute (awarded to P.C.S.).

Top

References

  1. Matkovic  E, Hoang Johnson  DK, Staples  JE, Mora-Pinzon  MC, Elbadawi  LI, Osborn  RA, et al. Enhanced arboviral surveillance to increase detection of Jamestown Canyon virus infections, Wisconsin, 2011–2016. Am J Trop Med Hyg. 2019;100:44551. DOIPubMedGoogle Scholar
  2. Patriquin  G, Drebot  M, Cole  T, Lindsay  R, Schleihauf  E, Johnston  BL, et al. High seroprevalence of Jamestown Canyon virus among deer and humans, Nova Scotia, Canada. Emerg Infect Dis. 2018;24:11821. DOIPubMedGoogle Scholar
  3. Pastula  DM, Hoang Johnson  DK, White  JL, Dupuis  AP II, Fischer  M, Staples  JE. Jamestown Canyon virus disease in the United States—2000–2013. Am J Trop Med Hyg. 2015;93:3849. DOIPubMedGoogle Scholar
  4. Bennett  RS, Nelson  JT, Gresko  AK, Murphy  BR, Whitehead  SS. The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys. Virol J. 2011;8:136. DOIPubMedGoogle Scholar
  5. Huang  C, Campbell  W, Grady  L, Kirouac  I, LaForce  FM. Diagnosis of Jamestown Canyon encephalitis by polymerase chain reaction. Clin Infect Dis. 1999;28:12947. DOIPubMedGoogle Scholar
  6. Savard  M, Paradis  A, Francoeur  CL. Jamestown Canyon encephalitis with NORSE and electrographic response to ribavirin: a case report. Epilepsia Open. 2018;3:2869. DOIPubMedGoogle Scholar
  7. Curren  EJ, Lehman  J, Kolsin  J, Walker  WL, Martin  SW, Staples  JE, et al. West Nile virus and other nationally notifiable arboviral diseases—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:113742. DOIPubMedGoogle Scholar
  8. Wilson  MR, Sample  HA, Zorn  KC, Arevalo  S, Yu  G, Neuhaus  J, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. N Engl J Med. 2019;380:232740. DOIPubMedGoogle Scholar
  9. Armstrong  PM, Andreadis  TG. Genetic relationships of Jamestown Canyon virus strains infecting mosquitoes collected in Connecticut. Am J Trop Med Hyg. 2007;77:115762. DOIPubMedGoogle Scholar
  10. Kinsella  CM, Paras  ML, Smole  S, Mehta  S, Ganesh  V, Chen  LH, et al. Jamestown Canyon virus in Massachusetts: clinical case series and vector screening. Emerg Microbes Infect. 2020;9:90312. DOIPubMedGoogle Scholar
  11. Solomon  IH, Spera  KM, Ryan  SL, Helgager  J, Andrici  J, Zaki  SR, et al. Fatal Powassan encephalitis (deer tick virus, lineage II) in a patient with fever and orchitis receiving rituximab. JAMA Neurol. 2018;75:74650. DOIPubMedGoogle Scholar
  12. Levi  ME, Quan  D, Ho  JT, Kleinschmidt-Demasters  BK, Tyler  KL, Grazia  TJ. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant. 2010;24:2238. DOIPubMedGoogle Scholar
  13. Yang  Y, Qiu  J, Snyder-Keller  A, Wu  Y, Sun  S, Sui  H, et al. Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy. Am J Hematol. 2018;93:5904. DOIPubMedGoogle Scholar
  14. Elliott  RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014;12:67385. DOIPubMedGoogle Scholar
  15. Garry  CE, Garry  RF. Proteomics computational analyses suggest that the antennavirus glycoprotein complex includes a class I viral fusion protein (α-penetrene) with an internal zinc-binding domain and a stable signal peptide. Viruses. 2019;11:E750. DOIPubMedGoogle Scholar

Top

Figures
Table

Top

Cite This Article

DOI: 10.3201/eid2701.203448

Original Publication Date: November 30, 2020

1These authors contributed equally to this article.

2These senior authors contributed equally to this article.

3Current affiliation: Emory University, Atlanta, Georgia, USA.

Table of Contents – Volume 27, Number 1—January 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Isaac H. Solomon, Department of Pathology, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115, USA

Send To

10000 character(s) remaining.

Top

Page created: September 23, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external